Bile acid signaling: Mechanism for bariatric surgery, cure for NASH?

Digestive Diseases

Volumn 33, Issue 3, 2015, Pages 440-446

  Kohli, Rohit ^a,c   Myronovych, Andriy ^a,d   Tan, Brandon K ^a,c   Salazar Gonzalez, Rosa Maria ^a,c   Miles, Lili ^b   Zhang, Wujuan ^b   Oehrle, Melissa ^b   Sandoval, Darleen A ^d   Ryan, Karen K ^e   Seeley, Randy J ^d   Setchell, Kenneth D R ^b  

^a Division of Gastroenterology Hepatology and Nutrition   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bariatric surgery; Bile acid metabolism; Nonalcoholic fatty liver disease; Obesity

Indexed keywords

BILE ACID;

BARIATRIC SURGERY; BILE ACID BLOOD LEVEL; BILE ACID SYNTHESIS; CONFERENCE PAPER; DIET RESTRICTION; ENTEROHEPATIC CIRCULATION; FATTY LIVER; HUMAN; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SLEEVE GASTRECTOMY; VERTICAL SLEEVE GASTRECTOMY; WEIGHT REDUCTION; ANIMAL; BLOOD; COMPLICATION; GASTRECTOMY; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; BARIATRIC SURGERY; BILE ACIDS AND SALTS; GASTRECTOMY; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; SIGNAL TRANSDUCTION; WEIGHT LOSS;

EID: 84930583108     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000371699     Document Type: Conference Paper

References (51)

1. Popkin BM, Adair LS, Ng SW: Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev 2012; 70: 3-21.
2. Welsh JA, Karpen S, Vos MB: Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr 2013; 162: 496-500. e1.
3. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, Sorgato C, Zenari L, Bonora E: Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010; 53: 713-718.
4. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology 2011; 140: 124-131.
5. Musso G, Gambino R, Cassader M, Pagano G: A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104.
6. Sanyal AJ, Chalasani N, Kowdley KV, Mc-Cullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685.
7. Schauer PR, Kashyap SR, Wolski K, et al: Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 1567-1576.
8. Mingrone G, Panunzi S, De Gaetano A, et al: Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366: 1577-1585.
9. Stefater MA, Wilson-Perez HE, Chambers AP, Sandoval DA, Seeley RJ: All bariatric surgeries are not created equal: insights from mechanistic comparisons. Endocr Rev 2012; 33: 595-622.
10. Inge T, Xanthakos S: Obesity at the extremes: the eyes only see what the mind is prepared to comprehend. J Pediatr 2010; 157: 3-4.
11. Inge TH, Zeller MH, Jenkins TM, et al: Perioperative outcomes of adolescents undergoing bariatric surgery: the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study. JAMA Pediatr 2014; 168: 47-53.
12. Chambers AP, Jessen L, Ryan KK, et al: Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology 2011; 141: 950-958.
13. Myronovych A, Kirby M, Ryan KK, et al: Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner. Obesity (Silver Spring) 2014; 22: 390-400.
14. Rubino F, Gagner M, Gentileschi P, et al: The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004; 240: 236-242.
15. Karcz WK, Krawczykowski D, Kuesters S, Marjanovic G, Kulemann B, Grobe H, et al: Influence of sleeve gastrectomy on NASH and type 2 diabetes mellitus. J Obes 2011; 2011: 765473.
16. Fuchs C, Claudel T, Trauner M: Bile acid-mediated control of liver triglycerides. Semin Liver Dis 2013; 33: 330-342.
17. Patti ME, Houten SM, Bianco AC, et al: Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 2009; 17: 1671-1677.
18. Nakatani H, Kasama K, Oshiro T, Watanabe M, Hirose H, Itoh H: Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism 2009; 58: 1400-1407.
19. Jansen PL, van Werven J, Aarts E, Berends F, Janssen I, Stoker J, Schaap FG: Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis 2011; 29: 48-51.
20. Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N, Klein S: Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab 2013; 98:E708-E712.
21. Kohli R, Kirby M, Setchell KD, Jha P, Klustaitis K, Woollett LA, et al: Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesityrelated comorbidities. Am J Physiol Gastrointest Liver Physiol 2010; 299:G652-G660.
22. Kohli R, Setchell KD, Kirby M, Myronovych A, Ryan KK, Ibrahim SH, et al: A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology 2013; 154: 2341-2351.
23. Myronovych A, Salazar-Gonzalez RM, Ryan KK, Miles L, Zhang W, Jha P, et al: The role of small heterodimer partner in nonalcoholic fatty liver disease improvement after vertical sleeve gastrectomy in mice. Obesity (Silver Spring) 2014; 22: 2301-2311.
24. Adorini L, Pruzanski M, Shapiro D: Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012; 17: 988-997.
25. Cipriani S, Mencarelli A, Palladino G, Fiorucci S: FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010; 51: 771-784.
26. Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R, et al: FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014; 509: 183-188.
27. Zhang Y, Hagedorn CH, Wang L: Role of nuclear receptor SHP in metabolism and cancer. Biochim Biophys Acta 2011; 1812: 893-908.
28. Wang L, Lee YK, Bundman D, Han Y, Thevananther S, Kim CS, et al: Redundant pathways for negative feedback regulation of bile acid production. Dev Cell 2002; 2: 721-731.
29. Wang L, Liu J, Saha P, Huang J, Chan L, Spiegelman B, et al: The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes. Cell Metab 2005; 2: 227-238.
30. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-1418.
31. Wang L, Han Y, Kim CS, Lee YK, Moore DD: Resistance of SHP-null mice to bile acid-induced liver damage. J Biol Chem 2003; 278: 44475-44481.
32. Boulias K, Katrakili N, Bamberg K, Underhill P, Greenfield A, Talianidis I: Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO J 2005; 24: 2624-2633.
33. Yuk JM, Shin DM, Lee HM, Kim JJ, Kim SW, Jin HS, et al: The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors. Nat Immunol 2011; 12: 742-751.
34. Kir S, Kliewer SA, Mangelsdorf DJ: Roles of FGF19 in liver metabolism. Cold Spring Harb Symp Quant Biol 2011; 76: 139-144.
35. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-225.
36. Simonen M, Dali-Youcef N, Kaminska D, Venesmaa S, Kakela P, Paakkonen M, et al: Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obes Surg 2012; 22: 1473-1480.
37. Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, et al: The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012; 153: 3613-3619.
38. Ahmad NN, Pfalzer A, Kaplan LM: Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes (Lond) 2013; 37: 1553-1559.
39. Haeusler RA, Pratt-Hyatt M, Welch CL, Klaassen CD, Accili D: Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metab 2012; 15: 65-74.
40. Yang JS, Kim JT, Jeon J, Park HS, Kang GH, Park KS, et al: Changes in hepatic gene expression upon oral administration of taurineconjugated ursodeoxycholic acid in ob/ob mice. PloS One 2010; 5:e13858.
41. Yang ZX, Shen W, Sun H: Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol Int 2010; 4: 741-748.
42. Kang K, Schmahl J, Lee JM, Garcia K, Patil K, Chen A, et al: Mouse ghrelin-O-acyltransferase (GOAT) plays a critical role in bile acid reabsorption. FASEB J 2012; 26: 259-271.
43. Mottino AD, Hoffman T, Dawson PA, Luquita MG, Monti JA, Sanchez Pozzi EJ, et al: Increased expression of ileal apical sodium-dependent bile acid transporter in postpartum rats. Am J Physiol Gastrointest Liver Physiol 2002; 282:G41-G50.
44. Habegger KM, Al-Massadi O, Heppner KM, Myronovych A, Holland J, Berger J, et al: Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia. Gut 2014; 63: 1238-1246.
45. Ishibashi S, Schwarz M, Frykman PK, Herz J, Russell DW: Disruption of cholesterol 7-hydroxylase gene in mice. I. Postnatal lethality reversed by bile acid and vitamin supplementation. J Biol Chem 1996; 271: 18017-18023.
46. Pandak WM, Bohdan P, Franklund C, Mallonee DH, Eggertsen G, Bjorkhem I, et al: Expression of sterol 12-hydroxylase alters bile acid pool composition in primary rat hepatocytes and in vivo. Gastroenterology 2001; 120: 1801-1809.
47. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, et al: A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000; 6: 517-526.
48. Eloranta JJ, Jung D, Kullak-Ublick GA: The human Na +-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferatoractivated receptor-gamma coactivator-1, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Mol Endocrinol 2006; 20: 65-79.
49. Rost D, Herrmann T, Sauer P, Schmidts HL, Stieger B, Meier PJ, et al: Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: effect of ursodeoxycholate. Hepatology 2003; 38: 187-195.
50. Vos TA, Ros JE, Havinga R, Moshage H, Kuipers F, Jansen PL, et al: Regulation of hepatic transport systems involved in bile secretion during liver regeneration in rats. Hepatology 1999; 29: 1833-1839.
51. Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, Schlattjan M, et al: Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013; 57: 1394-1406.